دورية أكاديمية

Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient

التفاصيل البيبلوغرافية
العنوان: Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient
المؤلفون: Eleftheriadis T., Pissas G., Liakopoulos V., Stefanidis I.
المصدر: Journal of Immunotherapy ; https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103994430&doi=10.1097%2fCJI.0000000000000365&partnerID=40&md5=7f09743448de50c87a953d85f6ea380dTest
سنة النشر: 2021
المجموعة: University of Thessaly Institutional Repository / Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας
مصطلحات موضوعية: hepatitis B surface antigen, nivolumab, recombinant hepatitis B vaccine, hepatitis B antibody, hepatitis B vaccine, PDCD1 protein, human, programmed death 1 receptor, adult, antigen blood level, Article, cancer immunotherapy, case report, clinical article, disease predisposition, drug tolerability, electrochemiluminescence, follow up, hemodialysis patient, hepatitis B, humoral immunity, kidney hypoplasia, lung metastasis, lung nodule, male, memory cell, middle aged, nephrectomy, plasma cell, priority journal
الوصف: Immune checkpoint inhibitors by blocking specific inhibitory pathways induce T-cell-mediated tumor lysis. However, many remain to be elucidated about their effect on human humoral immunity. We evaluated the effect of the PD1 inhibitor nivolumab on humoral immunity by following the levels of antibodies against hepatitis B surface antigen (anti-HBs) in a hemodialysis patient successfully vaccinated against hepatitis B virus 5 years ago and now starting nivolumab for renal cell carcinoma lung metastases. Anti-HBs kinetics after administration of an extra vaccine dose were also evaluated. Nivolumab increased anti-HBs and facilitated a further increase following an additional vaccine dose. The observed time frame indicates that nivolumab boosts humoral immune response by affecting long-lived plasma cells and at least memory B cells. This may protect cancer patients from pathogens encountered in the past or against which vaccination has been performed and provide information for the emerging immune checkpoint inhibitors administration concept against chronic infectious diseases. © 2021 Lippincott Williams and Wilkins. All rights reserved.
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 15249557
العلاقة: http://hdl.handle.net/11615/71340Test
DOI: 10.1097/CJI.0000000000000365
الإتاحة: https://doi.org/10.1097/CJI.0000000000000365Test
http://hdl.handle.net/11615/71340Test
رقم الانضمام: edsbas.EDAEBE7F
قاعدة البيانات: BASE
ResultId 1
Header edsbas
BASE
edsbas.EDAEBE7F
857
3
Academic Journal
academicJournal
856.820373535156
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.EDAEBE7F&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doi.org/10.1097/CJI.0000000000000365# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Eleftheriadis+T%2E%22">Eleftheriadis T.</searchLink><br /><searchLink fieldCode="AR" term="%22Pissas+G%2E%22">Pissas G.</searchLink><br /><searchLink fieldCode="AR" term="%22Liakopoulos+V%2E%22">Liakopoulos V.</searchLink><br /><searchLink fieldCode="AR" term="%22Stefanidis+I%2E%22">Stefanidis I.</searchLink> )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Journal of Immunotherapy ; https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103994430&doi=10.1097%2fCJI.0000000000000365&partnerID=40&md5=7f09743448de50c87a953d85f6ea380d )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => University of Thessaly Institutional Repository / Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22hepatitis+B+surface+antigen%22">hepatitis B surface antigen</searchLink><br /><searchLink fieldCode="DE" term="%22nivolumab%22">nivolumab</searchLink><br /><searchLink fieldCode="DE" term="%22recombinant+hepatitis+B+vaccine%22">recombinant hepatitis B vaccine</searchLink><br /><searchLink fieldCode="DE" term="%22hepatitis+B+antibody%22">hepatitis B antibody</searchLink><br /><searchLink fieldCode="DE" term="%22hepatitis+B+vaccine%22">hepatitis B vaccine</searchLink><br /><searchLink fieldCode="DE" term="%22PDCD1+protein%22">PDCD1 protein</searchLink><br /><searchLink fieldCode="DE" term="%22human%22">human</searchLink><br /><searchLink fieldCode="DE" term="%22programmed+death+1+receptor%22">programmed death 1 receptor</searchLink><br /><searchLink fieldCode="DE" term="%22adult%22">adult</searchLink><br /><searchLink fieldCode="DE" term="%22antigen+blood+level%22">antigen blood level</searchLink><br /><searchLink fieldCode="DE" term="%22Article%22">Article</searchLink><br /><searchLink fieldCode="DE" term="%22cancer+immunotherapy%22">cancer immunotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22case+report%22">case report</searchLink><br /><searchLink fieldCode="DE" term="%22clinical+article%22">clinical article</searchLink><br /><searchLink fieldCode="DE" term="%22disease+predisposition%22">disease predisposition</searchLink><br /><searchLink fieldCode="DE" term="%22drug+tolerability%22">drug tolerability</searchLink><br /><searchLink fieldCode="DE" term="%22electrochemiluminescence%22">electrochemiluminescence</searchLink><br /><searchLink fieldCode="DE" term="%22follow+up%22">follow up</searchLink><br /><searchLink fieldCode="DE" term="%22hemodialysis+patient%22">hemodialysis patient</searchLink><br /><searchLink fieldCode="DE" term="%22hepatitis+B%22">hepatitis B</searchLink><br /><searchLink fieldCode="DE" term="%22humoral+immunity%22">humoral immunity</searchLink><br /><searchLink fieldCode="DE" term="%22kidney+hypoplasia%22">kidney hypoplasia</searchLink><br /><searchLink fieldCode="DE" term="%22lung+metastasis%22">lung metastasis</searchLink><br /><searchLink fieldCode="DE" term="%22lung+nodule%22">lung nodule</searchLink><br /><searchLink fieldCode="DE" term="%22male%22">male</searchLink><br /><searchLink fieldCode="DE" term="%22memory+cell%22">memory cell</searchLink><br /><searchLink fieldCode="DE" term="%22middle+aged%22">middle aged</searchLink><br /><searchLink fieldCode="DE" term="%22nephrectomy%22">nephrectomy</searchLink><br /><searchLink fieldCode="DE" term="%22plasma+cell%22">plasma cell</searchLink><br /><searchLink fieldCode="DE" term="%22priority+journal%22">priority journal</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Immune checkpoint inhibitors by blocking specific inhibitory pathways induce T-cell-mediated tumor lysis. However, many remain to be elucidated about their effect on human humoral immunity. We evaluated the effect of the PD1 inhibitor nivolumab on humoral immunity by following the levels of antibodies against hepatitis B surface antigen (anti-HBs) in a hemodialysis patient successfully vaccinated against hepatitis B virus 5 years ago and now starting nivolumab for renal cell carcinoma lung metastases. Anti-HBs kinetics after administration of an extra vaccine dose were also evaluated. Nivolumab increased anti-HBs and facilitated a further increase following an additional vaccine dose. The observed time frame indicates that nivolumab boosts humoral immune response by affecting long-lived plasma cells and at least memory B cells. This may protect cancer patients from pathogens encountered in the past or against which vaccination has been performed and provide information for the emerging immune checkpoint inhibitors administration concept against chronic infectious diseases. © 2021 Lippincott Williams and Wilkins. All rights reserved. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 15249557 )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => http://hdl.handle.net/11615/71340 )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1097/CJI.0000000000000365 )
Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1097/CJI.0000000000000365<br />http://hdl.handle.net/11615/71340 )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.EDAEBE7F )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1097/CJI.0000000000000365 ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => hepatitis B surface antigen [Type] => general ) [1] => Array ( [SubjectFull] => nivolumab [Type] => general ) [2] => Array ( [SubjectFull] => recombinant hepatitis B vaccine [Type] => general ) [3] => Array ( [SubjectFull] => hepatitis B antibody [Type] => general ) [4] => Array ( [SubjectFull] => hepatitis B vaccine [Type] => general ) [5] => Array ( [SubjectFull] => PDCD1 protein [Type] => general ) [6] => Array ( [SubjectFull] => human [Type] => general ) [7] => Array ( [SubjectFull] => programmed death 1 receptor [Type] => general ) [8] => Array ( [SubjectFull] => adult [Type] => general ) [9] => Array ( [SubjectFull] => antigen blood level [Type] => general ) [10] => Array ( [SubjectFull] => Article [Type] => general ) [11] => Array ( [SubjectFull] => cancer immunotherapy [Type] => general ) [12] => Array ( [SubjectFull] => case report [Type] => general ) [13] => Array ( [SubjectFull] => clinical article [Type] => general ) [14] => Array ( [SubjectFull] => disease predisposition [Type] => general ) [15] => Array ( [SubjectFull] => drug tolerability [Type] => general ) [16] => Array ( [SubjectFull] => electrochemiluminescence [Type] => general ) [17] => Array ( [SubjectFull] => follow up [Type] => general ) [18] => Array ( [SubjectFull] => hemodialysis patient [Type] => general ) [19] => Array ( [SubjectFull] => hepatitis B [Type] => general ) [20] => Array ( [SubjectFull] => humoral immunity [Type] => general ) [21] => Array ( [SubjectFull] => kidney hypoplasia [Type] => general ) [22] => Array ( [SubjectFull] => lung metastasis [Type] => general ) [23] => Array ( [SubjectFull] => lung nodule [Type] => general ) [24] => Array ( [SubjectFull] => male [Type] => general ) [25] => Array ( [SubjectFull] => memory cell [Type] => general ) [26] => Array ( [SubjectFull] => middle aged [Type] => general ) [27] => Array ( [SubjectFull] => nephrectomy [Type] => general ) [28] => Array ( [SubjectFull] => plasma cell [Type] => general ) [29] => Array ( [SubjectFull] => priority journal [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Eleftheriadis T. ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pissas G. ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Liakopoulos V. ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Stefanidis I. ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2021 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 15249557 ) [1] => Array ( [Type] => issn-locals [Value] => edsbas ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Journal of Immunotherapy ; https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103994430&doi=10.1097%2fCJI.0000000000000365&partnerID=40&md5=7f09743448de50c87a953d85f6ea380d [Type] => main ) ) ) ) ) ) )
IllustrationInfo